A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502282-24-00

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-503678-18-00

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP)

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502505-15-00

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502286-16-00

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-501783-18-00

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502000-73-00

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

https://clinicaltrials.gov/study/NCT07008378?cond=Multiple+Sclerosis

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

Effect of Bobath Therapy on Balance Alterations in Patients With Multiple Sclerosis

https://clinicaltrials.gov/study/NCT07006259?cond=Multiple+Sclerosis

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

https://clinicaltrials.gov/study/NCT07006805?cond=Multiple+Sclerosis

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS

Clinical trial of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis

https://www.chictr.org.cn/showproj.html?proj=273442

#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS